Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

Vale, Claire L., Tierney, Jayne F., Fisher, David, Adams, Richard Alexander ORCID: https://orcid.org/0000-0003-3915-7243, Kaplan, Richard, Maughan, Timothy Stanley, Parmar, Mahesh K. B. and Meade, Angela M. 2012. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treatment Reviews 38 (6) , pp. 618-625. 10.1016/j.ctrv.2011.11.002

Full text not available from this repository.

Abstract

Background: Randomised controlled trials (RCTs) of anti-EGFR monoclonal antibodies (MAb) in patients with advanced colorectal cancer (aCRC) have reported conflicting results. Methods: A systematic review of RCTs comparing standard treatments ± anti-EGFR MAbs was conducted. Hazard ratios (HR) for progression-free (PFS) and overall survival (OS) were derived for patients with wild-type (WT) and mutant KRAS. Prespecified analyses were conducted for line of treatment, MAb used, chemotherapy regimen, and choice of fluouropyrimidine. Trials using bevacizumab on both arms were included in a sensitivity analysis. Results: Fourteen eligible RCTs were identified, with results by KRAS status available for ten RCTs. For third line treatment, the effect of anti-EGFR MAbs depended on KRAS status (interaction p < 0.00001), with a PFS benefit for patients with WT KRAS only (HR = 0.43, 95% CI 0.35–0.52, p < 0.00001). For first and second line treatment, the effect also appeared to depend on KRAS status (interaction p = 0.0003), again with the PFS benefit only for patients with WT KRAS (HR = 0.83, 95% CI 0.76–0.90, p < 0.0001). Differences between trial results (heterogeneity p = 0.02, I2 = 62%) were best explained by the fluouropyrimidine used, with PFS benefits confined to trials combining MAbs alongside 5FU-based chemotherapy (HR = 0.77, 95% CI 0.70–0.85, p < 0.00001). There was no evidence of a PFS benefit when MAbs were given with bevacizumab. Conclusions: For aCRC patients with WT KRAS, there are clear benefits of anti-EGFR MAbs in the third line and in the first and second line, when used alongside infusional 5FU-based regimens. However, there is no benefit for patients with KRAS mutations.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	Colorectal cancer; Anti-EGFR therapy; Systematic review; Meta-analysis
Publisher:	Elsevier
ISSN:	0305-7372
Funders:	UK Medical Research Council
Last Modified:	21 Oct 2022 09:38
URI:	https://orca.cardiff.ac.uk/id/eprint/37180

Citation Data

Cited 89 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item